Recursion Pharmaceuticals: 2026 priorities and analyst outlook

What happened: On May 14, 2026, Morgan Stanley raised its price target on Recursion Pharmaceuticals (RXRX) to $5.50, a 44.7% increase from the previous target. This bullish move came after RXRX surged 9.51% on May 6, breaking two days of losses. The stock offers a 100% upside potential based on its 1-year median price target of $7, supporting a moderately bullish consensus. Recursion's AI-driven platform and strategic partnerships with industry giants drive this optimism.

Market impact: The biotechnology sector, particularly AI-driven drug discovery companies, is affected. RXRX's strong performance and positive analyst sentiment could attract more investors to the sector, potentially driving up valuations for similar companies like Schrödinger (SDGR).

What to watch next: Investors should monitor RXRX's business updates, expected in late May. Additionally, watch for any updates on RXRX's strategic partnerships and clinical trial progress. The 1-year median price target of $7 will also be a key level to observe.